Quantcast

Baxter Presents Positive Data on Gammagard: Severe Adverse Events

May 19, 2012

On April 27th, 2012, Baxter, the company manufacturing Gammagard, announced positive Phase III clinical data of Gammagard Liquid 10% [Immune Globulin Intravenous (Human)], used for treating multifocal motor neuropathy (MMN). Gammagard is an intravenous solution that is made from human plasma. It is a sterile solution, which helps the body maintain immunity and fight disease. In February 1994, Baxter announced it was removing Gammagard from the global market because of the possibility that it may have transmitted the hepatitis virus, including hepatitis C. Now, AttorneyOne.com, a recognized authority on law, can provide helpful, proven advice and simple solutions including how to get in contact with legal counsel so anyone can easily and inexpensively deal with cases of Gammagard severe adverse events. http://www.attorneyone.com/gammagard-lawsuits/

San Diego, CA (PRWEB) May 18, 2012

The media spotlight is often a double-edged sword. No one knows this better than people who suffer from Gammaguard severe adverse events. And yet, gossip and rumor-mongering aside, the real story here is being overlooked according to Sean Burke of AttorneyOne.

On April 27th, 2012, Baxter International, the company manufacturing Gammagard, announced positive Phase III clinical data of Gammagard Liquid 10% [Immune Globulin Intravenous (Human)], used for treating multifocal motor neuropathy (MMN). Gammagard is an intravenous solution that is made from human plasma. It is a sterile solution, which helps the body maintain immunity and fight disease. According to the announcement, Gammagard Liquid met its two primary efficacy endpoints.

In February 1994, Baxter announced it was removing Gammagard from the global market because of the possibility that it may have transmitted the hepatitis virus, including hepatitis C. As the FDA said in July 1995, as many as 1,000 cases of hepatitis C could have been linked to use of Gammagard.

In September 2000, the U.S.D.C. for the Central District of California approved a settlement of the class action (MDL NO. 95-1060-R) providing financial compensation for U.S. individuals who used Gammagard between January 1993 and February 1994.

AttorneyOne.com, a recognized authority on law, can provide helpful advice and simple solutions including how to get in contact with legal counsel so that, in case of Gammagard severe adverse events, someone can easily and inexpensively deal with it. As Mr. Burke, director of Media Relations for AttorneyOne.com, added, “What all this information really illustrates is that threat from Gammagard remains. For that reason, our focus should squarely fall on getting the word out and assisting people in finding the right legal assistance.”

In October 2011, the FDA announced the recall of specific Gammagard Liquid [Immune Globulin Intravenous (Human)] 10% lots as a precautionary measure after the supplier of the glass vials that contain Gammagard Liquid notified Baxter of the possibility that there may be metallic particles partially embedded in the glass on the interior surface of the vial.

If someone has recently been diagnosed with Hepatitis C and has taken Gammagard, he/she might be able to file a Gammagard lawsuit.

AttorneyOne.com has further information on Gammagard lawsuits including how to get in contact with legal counsel.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Gammagard at our website. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2012/5/prweb9506870.htm.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/5/prweb9517268.htm


Source: prweb



comments powered by Disqus